20230522_Contact_Envelope

About DENARASE® High Salt

How it works
DENARASE® High Salt is an engineered version of the wild-type Serratia marcescens endonuclease, which is commonly used for DNA removal applications in bioprocessing. Compared to the wild-type DENARASE® a few amino acids were substituted to provide the enzyme with an improved salt tolerance without losing its specificity for nucleic acids. DENARASE® High Salt shows higher activity over a wider range of salt concentrations and pH levels and so offers greater flexibility in bioprocessing.
Because of the great similarities to the wild-type enzyme, DENARASE® High Salt can be detected using the same Serratia marcescens endonuclease ELISA Kits, such as DENARASE® ELISA Kit.

Production of DENARASE® High Salt
DENARASE® High Salt is produced using our established, proprietary DENARASE® manufacturing process which is based on the expression in a gram-positive Bacillus sp. strain. The enzyme is produced under ISO 9001 standard, without the use of antibiotics and raw materials of animal origin or TSE/BSE risk. 

DENARASE_High Salt_Group

DENARASE® - Best performance from low to high salt!

DENARASE® High Salt outcompetes other salt active nucleases (SAN) at process-relevant, elevated salt concentrations.
Relative DNA clearance compared to others
DENARASE®

  • Peak performance at low & physiological salt concentrations

  • Use of DENARASE® below 200 mM salt

DENARASE® High Salt

  • Designed to retain activity at elevated salt concentrations

  • Highest activity over the broadest spectrum of salt concentrations

  • Use of DENARASE® High Salt above 200 mM

Order & test DENARASE® High Salt now!

  • R&D-grade

    Products for use in research and development

    Intended for use in research and development applications and process development of biologicals such as viral vectors and vaccines. DENARASE® High Salt cleaves all forms of DNA and RNA and enables a simpler, more efficient harvest process at salt concentrations above 200 mM. 
     
    Purity: ≥ 99%​
    Activity: > 250 U/µl​
    Formulation:     Buffered aqueous glycerol solution
    Storage Temperature:     -20°C
    Estimated Delivery time:     1-2 weeks (depending on region)
     
    • Produced in conformity under ISO 9001 standard
    • Manufactured without the use of antibiotics, Triton X-100 and raw materials of animal origin
    • Net price excluding VAT and shipment costs
    DENARASE_High Salt_Group

    Choose your size for DENARASE® High Salt:

    Back to the section
  • GMP-grade

    DENARASE® High Salt GMP for biopharmaceutical manufacturing

    The launch of the DENARASE® High Salt GMP grade for use in commercial manufacturing processes of biologicals is scheduled for Q2 2025.

    • The manufacturing process of the High Salt GMP-grade will comply with the same regulations and standards as our well-known wild-type GMP-grade DENARASE® products. 

    • Produced under EU GMP conditions. 

    • Manufacturing free of animal-derived raw materials, Triton X-100 and antibiotics 

    • From a technical performance perspective, DENARASE® High Salt R&D- and GMP-grade will be equal. 
    GMP Coming soon-3

    The launch of the GMP grade DENARASE® High Salt is projected to be in Q2 2025.

    Back to the section
  • Free Sample

Products for use in research and development

Intended for use in research and development applications and process development of biologicals such as viral vectors and vaccines. DENARASE® High Salt cleaves all forms of DNA and RNA and enables a simpler, more efficient harvest process at salt concentrations above 200 mM. 
 
Purity: ≥ 99%​
Activity: > 250 U/µl​
Formulation: Buffered aqueous glycerol solution
Storage Temperature: -20°C
Estimated Delivery time: 1-2 weeks (depending on region)
 
  • Produced in conformity under ISO 9001 standard
  • Manufactured without the use of antibiotics, Triton X-100 and raw materials of animal origin
  • Net price excluding VAT and shipment costs
DENARASE_High Salt_Group

Choose your size for DENARASE® High Salt:

DENARASE® High Salt GMP for biopharmaceutical manufacturing

The launch of the DENARASE® High Salt GMP grade for use in commercial manufacturing processes of biologicals is scheduled for Q2 2025.

  • The manufacturing process of the High Salt GMP-grade will comply with the same regulations and standards as our well-known wild-type GMP-grade DENARASE® products. 

  • Produced under EU GMP conditions. 

  • Manufacturing free of animal-derived raw materials, Triton X-100 and antibiotics 

  • From a technical performance perspective, DENARASE® High Salt R&D- and GMP-grade will be equal. 
GMP Coming soon-3

The launch of the GMP grade DENARASE® High Salt is projected to be in Q2 2025.

Ready to elevate your Viral Vector Bioprocessing?

DENARASE® expert team

DENARASE® - Your complete toolkit for DNA removal 
Pick the most efficient DENARASE® version for your application. 

c-LEcta-DENARASE-ELISA-Kit

The One-for-all Serratia marcescens ELISA Kit!

For the quantification of residual Serratia marcescens endonucleases including DENARASE® High Salt.

Development of DENARASE®

2024

Launch of DENARASE® High Salt

c-LEcta launched DENARASE® High Salt, an engineered version of its top-selling product DENARASE®.

The newest addition to the DENARASE® portfolio has been especially designed to retain activity at higher salt concentrations and a broad pH spectrum. These features provide customers with greater process flexibility and increased cost efficiency in viral vector manufacturing processes that benefit from elevated salt levels.

highsalt_Gruppe

2023

New sizes of R&D-grade DENARASE® available

c-LEcta has just launched additional sizes of DENARASE® for research and development use.

Being widely applied in biopharmaceutical R&D and manufacturing, DENARASE sizes of 1 MU and 5 MU will now also be available as R&D-grade, in addition to GMP-grade.



R&D

2022

Global application of DENARASE® and ELISA Kit in biopharma­ceutical manufacturing

DENARASE® and ELISA Kit are established highest-quality products, applied in the manufacturing of viral vectors for Gene therapies and vaccines:
> 150 customers in > 30 countries
DENARASE® is applied in 4 Commercial and 40+ Clinical Phase I-III viral vector manufacturing processes

AdobeStock_335262300_Preview-1

2021

Drug Master File for DENARASE® accepted by FDA

Dedicated regulatory support for US-market approvals of pharmaceutical products via own US FDA Drug Master File.

In addition, certified compliance with the EXCiPACT and ANSI NSF 363 Standard (meeting GMP for pharmaceutical excipients)

EXCIPACT-Collage

2020

COVID-Support

Focused support for customers developing and manufacturing COVID-19 vaccines at unprecedented speed
Concerted efforts of c-LEcta teams with COVID-19 vaccine customers succeeded in the delivery of large, unplanned quantities of DENARASE on short timelines
c-LEcta’s resilient manufacturing and distribution network kept COVID-19 related supply issues to general customers at an absolute minimum

c-LEcta-covid-vaccine-1

2020

Launch of DENARASE® ELISA Kit

Launch of own ELISA kit for the detection of S. marcescens endonucleases in process-derived samples

Fastest and most sensitive ELISA kit available on the market

ELISA-Kit_1000x1000

2017

First DENARASE®-related patents granted

Patents were successfully granted for the production technology of DENARASE® based on recombinant expression in Bacillus

DENARASE-Patent-USA

2012

Product launch of DENARASE®

DENARASE® fulfills highest quality standards for biopharmaceutical manufacturing

Starting to build a global sales and distribution network for life science customers

Growth of internal quality, production, distribution and sales functions

DENARASE_1000x1000

2012

Manufacturing of DENARASE® under GMP conditions

Requirements of the biopharmaceutical industry for a GMP product were identified

Partnering with a contract manufacturing organization (CMO) to produce DENARASE® under EU GMP conditions

Manufacturing process free of animal derived raw materials and antibiotics was established

Production_1000x1000

2009-2012

Start of DENARASE® project: Strain selection, development of upstream and purification process

Project started: Application of en­do­nu­clea­ses for DNA removal during protein purification

c-LEcta‘s Bacillus strain, an endotoxin-free expression host, yielded highly active DENARASE product. Purity of ≥99 % was achieved after purification.

Fermenter_1000x1000
Generated with Avocode.Pfad 1179 Generated with Avocode.Pfad 1179

Get in touch with our DENARASE® expert team!

Vaishnavi Devarakonda

Vaishnavi Devarakonda
DENARASE® Sales

Need support? Contact me!
Melissa Rangel

Melissa Rangel
DENARASE® Sales

Need support? Contact me!

Cynthia Hofmann-Orsetti

Cynthia Hofmann-Orsetti
DENARASE® Sales

Need support? Contact me!